Share on StockTwits

Greatbatch (NYSE:GB) CEO Thomas J. Hook unloaded 1,790 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $45.33, for a total transaction of $81,140.70. Following the transaction, the chief executive officer now directly owns 147,224 shares of the company’s stock, valued at approximately $6,673,664. The sale was disclosed in a filing with the SEC, which is available at this link.

GB has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Greatbatch in a research note on Monday, August 25th. They now have a $48.00 price target on the stock. Analysts at KeyCorp reiterated a “buy” rating on shares of Greatbatch in a research note on Friday, June 13th. They now have a $58.00 price target on the stock, up previously from $55.00.

Greatbatch (NYSE:GB) traded up 1.56% on Wednesday, hitting $45.61. 170,357 shares of the company’s stock traded hands. Greatbatch has a 1-year low of $33.24 and a 1-year high of $51.64. The stock has a 50-day moving average of $47.45 and a 200-day moving average of $46.79. The company has a market cap of $1.136 billion and a price-to-earnings ratio of 24.07.

Greatbatch (NYSE:GB) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.60 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.59 by $0.01. The company had revenue of $172.10 million for the quarter, compared to the consensus estimate of $177.06 million. During the same quarter in the prior year, the company posted $0.56 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. On average, analysts predict that Greatbatch will post $2.33 earnings per share for the current fiscal year.

Greatbatch, Inc (NYSE:GB) is developer and manufacturer of components for implantable medical devices (IMDs) and Electrochem batteries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.